EP Patent

EP2393808B1 — Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

Assigned to Merck Sharp and Dohme LLC · Expires 2019-05-08 · 7y expired

What this patent protects

Patent listed against tedizolid-phosphate.

Drugs covered by this patent

Patent Metadata

Patent number
EP2393808B1
Jurisdiction
EP
Classification
—
Expires
2019-05-08
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.